Company
Mediwound, LTD
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
2
Originals and new uses
Phase 3 trials
4
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (1)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- EX-03EscharEx, 5% EscharExPhase 33 trials
MediWound Ltd · Venous Leg Ulcer (VLU), Venus Leg Ulcers
Recruiting Phase 3 trials
Largest first.
- A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)Pivotal-lookingRecruiting
MediWound LtdIndustry
NCT06568627 · 216 participants (planned) · Start Jun 1, 2025 · Primary completion Dec 2026
Drug: EscharEx (EX-03); Placebo (Gel vehicle) · For: Venous Leg Ulcer (VLU)
Sites: Phoenix, Arizona; Fresno, California; Los Angeles, California · 60 sites in all
Marketed drugs (1)
Newest FDA action first.
- Nexobrid Anacaulase-Bcdb · 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.